Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing NCI-designated Comprehensive Cancer Research Center dedicated to research and training, with the mission of changing and setting the standards of treatment, prevention and control of cancer through inpatient and outpatient care. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental and Stem Cell Biology, Genomic Integrity, and Molecular Structure);Bridge Research (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences);and Patient-Oriented Research (Clinical Research and Survivorship, Outcomes and Risk). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the 10 research programs depends on services provided by 34 core facilities. We are requesting funding from the Cancer Center Support Grant (CCSG) for 21 of these core facilities. During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs in key research areas. Support is requested to provide developmental funding for the laboratories of new investigators recruited in research areas aligned with the Center's strategic vision, to support cross-disciplinary pilot projects in population science research, and to support the core facilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-48S2
Application #
8917581
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2018-12-31
Budget Start
2014-09-01
Budget End
2014-12-31
Support Year
48
Fiscal Year
2014
Total Cost
$115,999
Indirect Cost
$49,333
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Choi, Karmel W; Shaffer, Kelly M; Zale, Emily L et al. (2018) Early Risk and Resiliency Factors Predict Chronic Posttraumatic Stress Disorder in Caregivers of Patients Admitted to a Neuroscience ICU. Crit Care Med 46:713-719
Kantor, Elizabeth D; Newton, Christina C; Giovannucci, Edward L et al. (2018) Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 29:389-397
Mizrachi, Aviram; Migliacci, Jocelyn C; Montero, Pablo H et al. (2018) Neck recurrence in clinically node-negative oral cancer: 27-year experience at a single institution. Oral Oncol 78:94-101
Fassel, Hannah; Bussel, James B; Roberts, Stephen S et al. (2018) Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. J Pediatr Hematol Oncol :
Lezcano, Cecilia; Shoushtari, Alexander N; Ariyan, Charlotte et al. (2018) Primary and Metastatic Melanoma With NTRK Fusions. Am J Surg Pathol 42:1052-1058
Bello, Danielle M; Russell, Christy; McCullough, Debbie et al. (2018) Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology. Ann Surg Oncol 25:2884-2889
Coriddi, Michelle; Kenworthy, Elizabeth; Weinstein, Andrew et al. (2018) The importance of indocyanine green near-infrared fluorescence angiography in perfusion assessment in vascularized omentum lymphatic transplant. J Surg Oncol 118:109-112
Korenstein, Deborah; Husain, Solomon; Gennarelli, Renee L et al. (2018) Impact of Clinical Specialty on Attitudes Regarding Overuse of Inpatient Laboratory Testing. J Hosp Med 13:844-847
Wang, Lucia; Guillen, Valeria S; Sharma, Naina et al. (2018) New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons. ACS Med Chem Lett 9:803-808
Offin, Michael; Rizvi, Hira; Tenet, Megan et al. (2018) Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clin Cancer Res :

Showing the most recent 10 out of 8799 publications